Literature DB >> 4168588

Effect of phenyramidol and bishydroxycoumarin on the metabolism of tolbutamide in human subjects.

H M Solomon, J J Schrogie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4168588     DOI: 10.1016/0026-0495(67)90097-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  8 in total

1.  [Changes in the velocity of drug catabolism and their importance in drug therapy].

Authors:  G F Kahl
Journal:  Klin Wochenschr       Date:  1971-04-01

2.  [Influence of liver diseases and kidney function disorders and phenylbutazone, phenprocoumarol and doxycycline on the excretion of glycodiazine].

Authors:  H Held; B Kaminski; H F von Oldershausen
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

Review 3.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

4.  Displacement of phenprocoumon (Marcumar) from albumin by sulfonylurea compounds, suramin, and ioglycamic acid.

Authors:  B Hüthwohl; E Jähnchen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

Review 5.  Drug interactions with oral sulphonylurea hypoglycaemic drugs.

Authors:  J M Hansen; L K Christensen
Journal:  Drugs       Date:  1977-01       Impact factor: 9.546

6.  Pharmacokinetic analysis of the interaction between dicoumarol and tolbutamide in man.

Authors:  E Jähnchen; T Meinertz; H J Gilfrich; U Groth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

Review 7.  Antihyperglycaemic agents. Drug interactions of clinical importance.

Authors:  A J Scheen; P J Lefèbvre
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

Review 8.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.